NDAORALFOR SUSPENSION2 Generics Approved
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ciprofloxacin (CIPRO) is a fluoroquinolone antibiotic approved in 1997 for treating bacterial infections via oral suspension. It works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication in susceptible organisms. CIPRO is indicated for a broad spectrum of bacterial infections including respiratory tract, urinary tract, skin, bone, and gastrointestinal infections.
$0.396MPart D
LOE ApproachingAs CIPRO approaches loss of exclusivity with moderate competitive pressure (60/100), the brand team is likely focused on managed decline and specialty positioning rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Ciprofol, Propofol and Sevoflurane for Postoperative Delirium in Elderly Brain Tumor Patients
Started Sep 2026
381 enrolled
Brain NeoplasmsDelirium - Postoperative
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Started Mar 2026
1,524 enrolled
Metastatic Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
Started Apr 2025
2,627 enrolled
Neisseria Gonorrheae Infection
Improving the Perception of Stress and Mutuality in Caregivers (MI-DEAR Study) of Migraine Patients With Depressive Symptoms Treated With Fremanezumab: A Study to Evaluate Whether Fremanezumab Reduces the Impact on Caregivers and Increases Couple Reciprocity
Started Oct 2024
308 enrolled
Migraine
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
Started Apr 2023
64 enrolled
Healthy Subjects
Worked on CIPRO at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.